`
`
`
`
`
`
`
`
`
`
`
`
`
`Exhibit 12
`
`
`
`
`
`
`
`REGENERON PHARMACEUTICALS, INC.,
`
`
`
`
`MYLAN PHARMACEUTICALS INC.,
`
`
`
`
`Plaintiff,
`
`
`v.
`
`
`
`Defendant.
`
`
`
`Case No. 1:22-cv-00061-TSK
`
`JURY TRIAL DEMANDED
`
`CONFIDENTIAL – SUBJECT TO
`PROTECTIVE ORDER
`
`Case 1:22-cv-00061-TSK-JPM Document 620 Filed 09/01/23 Page 2 of 21 PageID #: 48039
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE NORTHERN DISTRICT OF WEST VIRGINIA
`CLARKSBURG DIVISION
`
`
`
`
`FINAL INFRINGEMENT CONTENTIONS OF PLAINTIFF REGENERON
`PHARMACEUTICALS, INC. FOR U.S. PATENT NO. 11,104,715
`
`Plaintiff Regeneron Pharmaceuticals, Inc. (“Regeneron”) discloses the following final
`
`infringement contentions regarding U.S. Patent No. 11,104,715 (“the ’715 patent”) to Defendant
`
`Mylan Pharmaceuticals Inc. (“Mylan”). Regeneron is presently asserting claims 2, 3, 4, 6, 12,
`
`13, 14, 15, and 16 from the ’715 patent.
`
`Regeneron’s infringement contentions are based on the information currently available
`
`to, and known by, Regeneron. Regeneron has only received a limited set of documents from
`
`Mylan and has not yet received samples. Regeneron has also not yet obtained complete
`
`discovery from third parties that may have information relevant to this patent. Regeneron has
`
`also not yet obtained deposition testimony from a number of Mylan witnesses who may have
`
`knowledge relevant to this patent. Furthermore, the Court has not yet construed any of the
`
`asserted claims of this patent. As a result, Regeneron reserves the right to modify, amend, or
`
`otherwise supplement these infringement contentions as the pre-trial phase of the litigation
`
`proceeds and as additional information comes to light, and as provided in the case Scheduling
`
`1
`
`
`
`Case 1:22-cv-00061-TSK-JPM Document 620 Filed 09/01/23 Page 3 of 21 PageID #: 48040
`
`Order, the Federal Rules of Civil Procedure, and the Local Rules of the Northern District of West
`
`Virginia.
`
`This claim chart is provided without prejudice to Regeneron’s right to introduce expert
`
`opinions and demonstratives as expert discovery progress, and to produce and introduce at trial
`
`all evidence, whenever discovered, related to the proof of currently known and subsequently
`
`discovered facts. In addition, the division of each claim into individual limitations below is for
`
`convenience only and is without prejudice to Regeneron’s right to argue for a different division
`
`
`
` CAREY DOUGLAS KESSLER & RUBY, PLLC
`
`/s/ Steven R. Ruby
`Steven R. Ruby (WVSB No. 10752)
`David R. Pogue (WVSB No. 10806)
`707 Virginia Street East
`901 Chase Tower (25301)
`P.O. Box 913
`Charleston, West Virginia 25323
`(304) 345-1234
`sruby@cdkrlaw.com
`drpogue@cdkrlaw.com
`
`
`
`at a later date.
`
`
`Date: January 12, 2023
`
`
`Of Counsel:
`
`David I. Berl (admitted PHV)
`Ellen E. Oberwetter (admitted PHV)
`Thomas S. Fletcher (admitted PHV)
`Andrew V. Trask (admitted PHV)
`Teagan J. Gregory (admitted PHV)
`Shaun P. Mahaffy (admitted PHV)
`Arthur J. Argall III (admitted PHV)
`Adam Pan (admitted PHV)
`Nicholas Jordan (admitted PHV)
`Renee M. Griffin (admitted PHV)
`Sean M. Douglass (admitted PHV)
`Haylee Bernal Anderson (admitted PHV)
`WILLIAMS & CONNOLLY LLP
`680 Maine Avenue, SW
`Washington, DC 20024
`(202) 434-5000
`dberl@wc.com
`eoberwetter@wc.com
`tfletcher@wc.com
`atrask@wc.com
`tgregory@wc.com
`smahaffy@wc.com
`
`2
`
`
`
`Case 1:22-cv-00061-TSK-JPM Document 620 Filed 09/01/23 Page 4 of 21 PageID #: 48041
`
`kkayali@wc.com
`aargall@wc.com
`apan@wc.com
`njordan@wc.com
`rgriffin@wc.com
`sdouglass@wc.com
`handerson@wc.com
`
`Andrew E. Goldsmith (admitted PHV)
`Evan T. Leo (admitted PHV)
`Jacob E. Hartman (admitted PHV)
`Mary Charlotte Y. Carroll (admitted PHV)
`Sven E. Henningson (admitted PHV)
`KELLOGG, HANSEN, TODD, FIGEL &
` FREDERICK, P.L.L.C.
`1615 M Street, NW, Suite 400
`Washington, DC 20036
`(202) 326-7900
`agoldsmith@kellogghansen.com
`eleo@kellogghansen.com
`jhartman@kellogghansen.com
`mcarroll@kellogghansen.com
`shenningson@kellogghansen.com
`
`Attorneys for Plaintiff Regeneron
`Pharmaceuticals, Inc.
`
`
`3
`
`
`
`Case 1:22-cv-00061-TSK-JPM Document 620 Filed 09/01/23 Page 5 of 21 PageID #: 48042
`Case 1:22-cv-00061-TSK-JPM Document 620 Filed 09/01/23 Page 5 of 21 PagelD #: 48042
`
`Infringement Contentions Regarding U.S. Patent No. 11,104,715 °715 Patent Claim
`
`
`
`Case 1:22-cv-00061-TSK-JPM Document 620 Filed 09/01/23 Page 6 of 21 PageID #: 48043
`
`1. A method of producing aflibercept
`harvested from a host cell cultured in
`a chemically defined medium
`(CDM), comprising:
`
`5
`
`
`
`Case 1:22-cv-00061-TSK-JPM Document 620 Filed 09/01/23 Page 7 of 21 PageID #: 48044
`Case 1:22-cv-00061-TSK-JPM Document 620 Filed 09/01/23 Page 7 of 21 PagelD #: 48044
`
`
`
`Infringement Contentions Regarding U.S. Patent No. 11,104,715 °715 Patent Claim
`
`
`
`Case 1:22-cv-00061-TSK-JPM Document 620 Filed 09/01/23 Page 8 of 21 PageID #: 48045
`
`
`(a) providing a hostcell genetically
`engineered to express aflibercept;
`
`(b) culturing said hostcell in
`said CDM underconditions suitable
`in whichsaid host cell expresses said
`aflibercept wherein the cumulative
`concentration of nickel in
`said CDMisless than or equalto 0.4
`uM orabout 0.4 uM and one or more
`of the following:
`
`Infringement Contentions Regarding U.S. Patent No. 11,104,715 °715 Patent Claim
`
`
`
`
`
`i. the cumulative concentration
`of iron in said CDM is less than or
`equal to 55.0 uM;
`
`u1. the cumulative concentration
`of copperin said CDM isless than or
`equal to 0.8 uM;
`
`Case 1:22-cv-00061-TSK-JPM Document 620 Filed 09/01/23 Page 9 of 21 PageID #: 48046
`
`Infringement Contentions Regarding U.S. Patent No. 11,104,715 °715 Patent Claim
`
`
`
`
`
`Case 1:22-cv-00061-TSK-JPM Document 620 Filed 09/01/23 Page 10 of 21 PageID #:
`48047
`
`
`
`Case 1:22-cv-00061-TSK-JPM Document 620 Filed 09/01/23 Page 11 of 21 PageID #:
`48048
`
`
`
`Case 1:22-cv-00061-TSK-JPM Document 620 Filed 09/01/23 Page 12 of 21 PageID #:
`48049
`
`
`
`Case 1:22-cv-00061-TSK-JPM Document 620 Filed 09/01/23 Page 13 of 21 PageID #:
`48050
`
`
`
`Case 1:22-cv-00061-TSK-JPM Document 620 Filed 09/01/23 Page 14 of 21 PageID #:
`48051
`
`
`
`Case 1:22-cv-00061-TSK-JPM Document 620 Filed 09/01/23 Page 15 of 21 PageID #:
`48052
`
`
`
`Case 1:22-cv-00061-TSK-JPM Document 620 Filed 09/01/23 Page 16 of 21 PageID #:
`48053
`
`
`
`Case 1:22-cv-00061-TSK-JPM Document 620 Filed 09/01/23 Page 17 of 21 PageID #:
`48054
`
`
`
`Case 1:22-cv-00061-TSK-JPM Document 620 Filed 09/01/23 Page 18 of 21 PageID #:
`48055
`
`
`
`Case 1:22-cv-00061-TSK-JPM Document 620 Filed 09/01/23 Page 19 of 21 PageID #:
`48056
`
`
`
`Case 1:22-cv-00061-TSK-JPM Document 620 Filed 09/01/23 Page 20 of 21 PageID #:
`48057
`
`
`
`Case 1:22-cv-00061-TSK-JPM Document 620 Filed 09/01/23 Page 21 of 21 PageID #:
`48058
`
`